[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640347":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":46,"collaborators":48,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":11,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":67,"conditions":68,"keywords":74,"overallStatus":78,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"The Charlotte and Gwenyth Gray Foundation","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group","EXPERIMENTAL",null,[13],"Drug: scAAV9.CB.CLN6 (dose: 1.5E14 vector genomes)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","scAAV9.CB.CLN6 (dose: 1.5E14 vector genomes)","self-complementary adeno-associated viral vector, serotype 9 (scAAV9), which contains the human CLN6 gene under the control of a hybrid CMV\u002FCB promoter",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Tiffany M Sepp","CONTACT","617-710-0770","tiffany@vanguardclinical.com",[27],{"facility":28,"status":11,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"University of California, San Diego - Rady Children's","La Jolla","California","92093","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-117.2742,32.84727,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":44,"email":45},"Olivia Kim-McManus, MD","858-576-1700","x224550","okimmcmanus@health.ucsd.edu",{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[49],{"name":50,"class":6},"University of California, San Diego","100640347","phase-1-gene-therapy-trial-for-cln6-batten-disease-100640347",false,"NCT07582484","Gene Therapy Trial for CLN6 Batten Disease","Phase 1\u002F2b Gene Transfer Clinical Trial for Variant Late Infantile Neuronal Ceroid Lipofuscinosis (CLN6 Batten Disease), Delivering the CLN6 Gene by Self-Complementary AAV9","Inclusion Criteria:\n\n* Diagnosis of CLN6\n* At least 4 months old\n\nExclusion Criteria:\n\n* Presence of another inherited neurologic disease\n* Prior stem cell transplantation\n* Prior gene transfer, gene editing, or viral vector therapy","ALL","4 Months",{"count":61,"type":62},12,"ESTIMATED","INTERVENTIONAL",[65,66],"PHASE1","PHASE2","The goal of this clinical trial is to learn if a gene therapy called scAAV9.CB.CLN6 can treat children with CLN6 Batten disease (variant late infantile neuronal ceroid lipofuscinosis). The main questions it aims to answer are if he gene therapy safe and well tolerated, and if the gene therapy help slow disease progression or improve symptoms.\n\nParticipants will:\n\nReceive a single dose of the gene therapy through an injection into the fluid around the spinal cord (intrathecal administration) Have regular study visits over 2 years for safety checks and assessments of disease progression Be followed for an additional 3 years in a long-term follow-up study",[69,70,71,72,73],"CLN6","Batten Disease","Batten's Disease","Neuronal Ceroid Lipofuscinosis CLN6","Neuronal Ceroid Lipofuscinosis",[69,75,76,77,73],"CLN6 Batten","Batten","Batten's","NOT_YET_RECRUITING","2026-05-12",{"date":81,"type":82},"2026-05-14","ACTUAL",{"date":84,"type":62},"2026-08",{"date":86,"type":62},"2028-08",{"name":5,"class":6},1]